Characteristics and Reporting of Number Needed to Treat, Number Needed to Harm, and Absolute Risk Reduction in Controlled Clinical Trials, 2001-2019

被引：10

作者：

Elliott, Marissa H. ^{[1
]}

Skydel, Joshua J. ^{[2
]}

Dhruva, Sanket S. ^{[3
]}

Ross, Joseph S. ^{[4
]}

Wallach, Joshua D. ^{[5
]}

机构：

[1] Yale Sch Publ Hlth, Dept Chron Dis Epidemiol, New Haven, CT USA

[2] Tufts Univ, Sch Med, Boston, MA 02111 USA

[3] Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA USA

[4] Yale Sch Med, Dept Internal Med, New Haven, CT USA

[5] Yale Sch Publ Hlth, Dept Environm Hlth Sci, 60 Coll St,4th Floor,Room 411, New Haven, CT 06510 USA

来源：

JAMA INTERNAL MEDICINE | 2021年 / 181卷 / 02期

关键词：

D O I：

10.1001/jamainternmed.2020.4799

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

This cross-sectional study assesses the trends and characteristics of absolute measure reporting in highly cited medical journals from 2001 to 2019.

引用

页码：282 / 284

页数：3

共 50 条

[31] Number Needed to Treat and Number Needed to Harm analysis of the zuranolone phase 2 clinical trial results in major depressive disorder
Arnaud, Alix
Suthoff, Ellison
Stenson, Katie
Werneburg, Brian
Hodgkins, Paul
Bonthapally, Vijayveer
Jonas, Jeffrey
Meyer, Kellie
O'Day, Ken
JOURNAL OF AFFECTIVE DISORDERS, 2021, 285 : 112 - 119
[32] Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed
Citrome, L.
Ketter, T.
Cucchiaro, J.
Loebel, A.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2014, 17 : 54 - 54
[33] Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed
Citrome, Leslie
Ketter, Terence A.
Cucchiaro, Josephine
Loebel, Antony
JOURNAL OF AFFECTIVE DISORDERS, 2014, 155 : 20 - 27
[34] Clinical Assessment of Lurasidone Benefit and Risk in the Treatment of Bipolar I Depression Using Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed
Citrome, Leslie
Ketter, Terence A.
Cucchiaro, Josephine
Loebel, Antony
NEUROPSYCHOPHARMACOLOGY, 2013, 38 : S359 - S361
[35] Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed
Ketter, T. A.
Citrome, L.
Cucchiaro, J.
Loebel, A.
BIPOLAR DISORDERS, 2013, 15 : 92 - 92
[36] Using both "relative risk reduction" and "number needed to treat" in evaluating primary and secondary clinical trials of lipid reduction
Moriarty, PM
AMERICAN JOURNAL OF CARDIOLOGY, 2001, 87 (10): : 1206 - +
[37] Clinical statistics for primary care practitioners: Part II - Absolute risk reduction, relative risk, relative risk reduction, and number needed to treat
McHugh, Mary L.
JOURNAL FOR SPECIALISTS IN PEDIATRIC NURSING, 2008, 13 (02) : 135 - 138
[38] The Number Needed to Treat: 25 Years of Trials and Tribulations in Clinical Research
Suissa, Samy
RAMBAM MAIMONIDES MEDICAL JOURNAL, 2015, 6 (03):
[39] Lumateperone for the Treatment of Schizophrenia: Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed br br
Citrome, Leslie
Durgam, Suresh
Edwards, John B.
Davis, Robert E.
JOURNAL OF CLINICAL PSYCHIATRY, 2023, 84 (02)
[40] Daridorexant for patients with chronic insomnia disorder: number needed to treat, number needed to harm, and likelihood to be helped or harmed
Chalet, Francois-Xavier
Luyet, Pierre-Philippe
Rabasa, Cristina
Vaillant, Cedric
Saskin, Paul
Ahuja, Ajay
Citrome, Leslie
POSTGRADUATE MEDICINE, 2024, 136 (04) : 396 - 405

← 1 2 3 4 5 →